{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:00:01Z","timestamp":1791129601644,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":602,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Bacterial overgrowth of the small intestine is a condition characterized by nutrient malabsorption due to an excessive number of bacteria in the lumen of the small intestine. Current treatment is based on empirical courses of broad spectrum antibiotics; few controlled data, with respect to the duration and choice of antibiotic drug, exist at present. The recent availability of rifaximin, a non\u2010absorbable rifamycin derivative, highly effective against anaerobic bacteria, prompted us to carry out a randomized, double\u2010blind controlled trial in order to compare its efficacy and tolerability to those of tetracycline, currently considered the first\u2010choice drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In 21 patients affected by small intestinal bacterial overgrowth, fasting, peak and total H<jats:sub>2<\/jats:sub> excretion after ingestion of 50\u2003g glucose and severity of symptoms were evaluated before and after a 7\u2010day course of rifaximin, 1200\u2003mg\/day (400\u2003 mg t.d.s.), or chlortetracycline, 1\u2003g\/day (333\u2003mg\u2423t.d.s.).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Fasting, peak and total H<jats:sub>2<\/jats:sub> excretion decreased significantly in the group of patients treated with rifaximin whereas chlortetracycline did not modify these parameters. The H<jats:sub>2<\/jats:sub> breath test normalized in 70% of patients after rifaximin and in 27% of patients after chlortetracycline. The improvement in symptoms was significantly higher in patients treated with rifaximin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Rifaximin is a promising, easily\u2010handled and safe drug for the short\u2010term treatment of small intestinal bacterial overgrowth.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00751.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:41:28Z","timestamp":1047354088000},"page":"551-556","source":"Crossref","is-referenced-by-count":122,"title":["Rifaximin versus chlortetracycline in the short\u2010term treatment of small intestinal bacterial overgrowth"],"prefix":"10.1111","volume":"14","author":[{"family":"Di Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Malservisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Veneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ferrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(79)91337-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(81)90150-5"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6395.789"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01345304"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252102"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70336-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238165"},{"key":"e_1_2_6_9_2","first-page":"365","article-title":"In vitro activity of rifaximin and rifampicin against some anaerobic bacteria","volume":"6","author":"Lamanna A","year":"1984","journal-title":"Chemioterapia"},{"key":"e_1_2_6_10_2","first-page":"312","article-title":"Treatment of small intestine bacterial overgrowth with rifaximin, a non\u2010absorbable rifamycin","volume":"16","author":"Corazza GR","year":"1988","journal-title":"J Lnt Med Res"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90173-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/0016-5085(84)90204-X","article-title":"Fasting breath hydrogen concentration: normal values and clinical application","volume":"87","author":"Perman JA","year":"1984","journal-title":"Gastroenterology"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90313-1"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0016-5085(86)90686-4","article-title":"lnfluence of the oropharyngeal microflora on the measurements of exhaled breath hydrogen","volume":"91","author":"Thompson DG","year":"1986","journal-title":"Gastroenterology"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/29.11.1980"},{"key":"e_1_2_6_16_2","first-page":"147","article-title":"Breath hydrogen (H2) response to carbohydrate malabsorption after exercise","volume":"102","author":"Payne DL","year":"1983","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_17_2","first-page":"798","article-title":"Modification of the breath hydrogen test increased sensitivity for the detection of carbohydrate malabsorption","volume":"100","author":"Kotler OP","year":"1982","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90475-Z"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90818-L"},{"key":"e_1_2_6_20_2","first-page":"110","article-title":"A critical appraisal of diagnostic tests for small intestinal bacterial overgrowth","volume":"9","author":"Riordan SM","year":"1996","journal-title":"Gastroenterol Internat"},{"key":"e_1_2_6_21_2","unstructured":"BanwellJG&YangP.Bacterial overgrowth syndrome. In: Bayless TM ed. Current Therapy in Gastrointestinal and Liver Disease. Philadelphia: Decker 1986:15660."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90647-8"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/135.Supplement.S25"},{"key":"e_1_2_6_24_2","first-page":"409","article-title":"Tetracycline kinetics in undernourished subjects","volume":"19","author":"Raghuram TC","year":"1981","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_6_25_2","unstructured":"GoodmanLS&GilmanA. The Pharmacological Basis of Therapeutics. London: Tindall 1991:11701170."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00751.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00751.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00751.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T17:10:44Z","timestamp":1698599444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00751.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00751.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00751.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}